… How drug disposition and clearance differ between relatively healthy preterm neonates
and those with multiple comorbid diagnoses is an important area for future development. …

… PK/PD modeling has been employed in NOWS pharmacotherapies to characterize the
interpatient variability in drug disposition and effect, the exposure-response relationship, and to …

… therapeutic hypothermia or extracorporeal life support, preterm infants, infants who need a
tailored dose of anticancer drugs. … options for a personalized therapy in newborns and infants. …

… Children should not be treated as “miniature men and … newborn child less than a year
to the adolescent due to the premature physiological process, which interferes with medicine …

… the drug(s) being used. While our understanding of the impact of ontogeny on drug disposition
… and disease on drug response and pharmacodynamics, as well as in emerging areas of …

… predict pediatric drug disposition and first-in child dose to ensure safer use of drugs in children,
… The current practice of pediatric dose selection is based on body weight or body surface …

… thus contributing to an onset of action that is rapid and a duration of action that is prolonged.
As a Biopharmaceutics Drug Disposition Classification System Class I drug, high solubility, …

… Half-life is lower in preterm and term infants (40 to 60 hours) compared to children (< 20
hours) because renal function is lower in infants, and it increases with infant maturation. …

… predict the dose-response relationship of a drug in sick children, and because the association
between body size and drug disposition is not the same for all children (21). In addition, …

… Pharmacokinetic-pharmacodynamic modeling and its clinical translation has proven useful
for understanding drug disposition and effect in pediatric anesthesia. To demonstrate how …